{"id":"https://openalex.org/W4310107785","doi":"https://doi.org/10.1182/blood-2022-163565","title":"Risk of Therapy-Related Acute Myeloid Leukemia (t-AML) in Cancer Patients Treated with Chemotherapy with or without Radiotherapy: A National Population-Based Cohort Study Using SEER Registry","display_name":"Risk of Therapy-Related Acute Myeloid Leukemia (t-AML) in Cancer Patients Treated with Chemotherapy with or without Radiotherapy: A National Population-Based Cohort Study Using SEER Registry","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310107785","doi":"https://doi.org/10.1182/blood-2022-163565"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-163565","doi":"https://doi.org/10.1182/blood-2022-163565","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-163565","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5015282610","display_name":"Julia H. Joo","orcid":"https://orcid.org/0009-0000-1299-8144","observed_orcids":["https://orcid.org/0009-0000-1299-8144"]},"institutions":[{"id":"https://openalex.org/I36373038","display_name":"Cleveland Clinic Lerner College of Medicine","ror":"https://ror.org/02x4b0932","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750","https://openalex.org/I36373038"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julia H. Joo","raw_affiliation_strings":["1Cleveland Clinic Lerner College of Medicine, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Cleveland Clinic Lerner College of Medicine, Cleveland, OH","institution_ids":["https://openalex.org/I36373038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100732042","display_name":"Yanwen Chen","orcid":"https://orcid.org/0000-0002-3467-2871","observed_orcids":["https://orcid.org/0000-0002-3467-2871","https://orcid.org/0000-0001-7959-5040"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yanwen Chen","raw_affiliation_strings":["2Quantitative Health Sciences, Cleveland Clinic, Cleveland,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Quantitative Health Sciences, Cleveland Clinic, Cleveland,","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023728016","display_name":"Aaron Thomas Gerds","orcid":"https://orcid.org/0000-0002-3422-1309","observed_orcids":["https://orcid.org/0000-0002-3422-1309"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron T. Gerds","raw_affiliation_strings":["3Department of Hematology and Medical Oncology,, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Hematology and Medical Oncology,, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082944296","display_name":"Anjali S. Advani","orcid":"https://orcid.org/0000-0003-0015-5902","observed_orcids":["https://orcid.org/0000-0003-0015-5902"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anjali Advani","raw_affiliation_strings":["4Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052906436","display_name":"Sophia Balderman","orcid":"https://orcid.org/0000-0001-8157-8725","observed_orcids":["https://orcid.org/0000-0001-8157-8725"]},"institutions":[{"id":"https://openalex.org/I1292894508","display_name":"Roswell Park Comprehensive Cancer Center","ror":"https://ror.org/0499dwk57","country_code":"US","type":"facility","lineage":["https://openalex.org/I1292894508"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sophia R. Balderman","raw_affiliation_strings":["5Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY","institution_ids":["https://openalex.org/I1292894508"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016810759","display_name":"Hetty E. Carraway","orcid":"https://orcid.org/0000-0001-5241-3614","observed_orcids":["https://orcid.org/0000-0001-5241-3614"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hetty E. Carraway","raw_affiliation_strings":["6Department of Hematology and Medical Oncology, Taussig Cancer institute, Leukemia Program, Cleveland Clinic, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Department of Hematology and Medical Oncology, Taussig Cancer institute, Leukemia Program, Cleveland Clinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042021797","display_name":"Abhay Singh","orcid":"https://orcid.org/0000-0001-6657-8647","observed_orcids":["https://orcid.org/0000-0001-6657-8647"]},"institutions":[{"id":"https://openalex.org/I1292894508","display_name":"Roswell Park Comprehensive Cancer Center","ror":"https://ror.org/0499dwk57","country_code":"US","type":"facility","lineage":["https://openalex.org/I1292894508"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Abhay Singh Singh","raw_affiliation_strings":["7Department of Internal Medicine, Division of Hematology, Roswell Park Comprehensive Cancer Center, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Department of Internal Medicine, Division of Hematology, Roswell Park Comprehensive Cancer Center, Cleveland, OH","institution_ids":["https://openalex.org/I1292894508"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102826236","display_name":"Sudipto Mukherjee","orcid":"https://orcid.org/0000-0002-8325-2603","observed_orcids":["https://orcid.org/0000-0002-8325-2603","https://orcid.org/0009-0002-0717-6319"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sudipto Mukherjee","raw_affiliation_strings":["6Department of Hematology and Medical Oncology, Taussig Cancer institute, Leukemia Program, Cleveland Clinic, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Department of Hematology and Medical Oncology, Taussig Cancer institute, Leukemia Program, Cleveland Clinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.16801054,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"140","issue":"Supplement 1","first_page":"687","last_page":"689"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T14078","display_name":"Multiple and Secondary Primary Cancers","score":0.8252000212669373,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T14078","display_name":"Multiple and Secondary Primary Cancers","score":0.8252000212669373,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.17190000414848328,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/therapy-related-acute-myeloid-leukemia","display_name":"therapy-related acute myeloid leukemia","score":0.9959999918937683},{"id":"https://openalex.org/keywords/chemotherapy","display_name":"chemotherapy","score":0.6539999842643738},{"id":"https://openalex.org/keywords/radiotherapy","display_name":"radiotherapy","score":0.9919999837875366},{"id":"https://openalex.org/keywords/cancer-survivors","display_name":"cancer survivors","score":0.640999972820282},{"id":"https://openalex.org/keywords/second-primary-malignancy","display_name":"second primary malignancy","score":0.5989999771118164},{"id":"https://openalex.org/keywords/leukemia-risk","display_name":"leukemia risk","score":0.4000000059604645},{"id":"https://openalex.org/keywords/standardized-incidence-ratio","display_name":"standardized incidence ratio","score":0.6230000257492065},{"id":"https://openalex.org/keywords/excess-absolute-risk","display_name":"excess absolute risk","score":0.8730000257492065},{"id":"https://openalex.org/keywords/excess-relative-risk","display_name":"excess relative risk","score":0.8149999976158142},{"id":"https://openalex.org/keywords/seer-database","display_name":"SEER database","score":0.5690000057220459},{"id":"https://openalex.org/keywords/cancer-treatment-complications","display_name":"cancer treatment complications","score":0.32199999690055847}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8570643663406372},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.629733681678772},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.550645112991333},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5408158898353577},{"id":"https://openalex.org/C2778527826","wikidata":"https://www.wikidata.org/wiki/Q1787017","display_name":"Cancer registry","level":3,"score":0.5341873168945312},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5291707515716553},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.5035540461540222},{"id":"https://openalex.org/C2779391198","wikidata":"https://www.wikidata.org/wiki/Q7647035","display_name":"Surveillance, Epidemiology, and End Results","level":4,"score":0.5024306774139404},{"id":"https://openalex.org/C107130276","wikidata":"https://www.wikidata.org/wiki/Q133805","display_name":"Epidemiology","level":2,"score":0.5012526512145996},{"id":"https://openalex.org/C2779399171","wikidata":"https://www.wikidata.org/wiki/Q1483951","display_name":"Malignancy","level":2,"score":0.47677022218704224},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.45148900151252747},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.44070667028427124},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.4404727816581726},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4293782114982605},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.41350075602531433},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.38622525334358215},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-163565","doi":"https://doi.org/10.1182/blood-2022-163565","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-163565","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4389231750","https://openalex.org/W2915944626","https://openalex.org/W4417019209","https://openalex.org/W4286296485","https://openalex.org/W1964462241","https://openalex.org/W2906323921","https://openalex.org/W4385697961","https://openalex.org/W2890649912","https://openalex.org/W4239463974","https://openalex.org/W2555724215"],"abstract_inverted_index":{"Background:":[0],"Therapy-related":[1],"AML":[2,119,203,210,223,312],"(t-AML)":[3],"is":[4,673,688],"a":[5,42,51,132,306],"rare":[6],"and":[7,19,79,86,94,110,162,217,322,361,411,434,457,472,505,588,608,634,641,667,681],"fatal":[8],"complication":[9],"in":[10,34,54,64,375,400,416,437,500,516,538,602,654,669],"cancer":[11,35,55,383,410,461,467,474,580,604,640],"patients":[12,56,556],"(pts)":[13],"previously":[14],"treated":[15,57,293,453,484],"with":[16,58,60,100,116,279,294,305,341,388,402,418,433,454,485,502,651,662],"chemotherapy":[17,514,676],"(CTX)":[18],"radiotherapy":[20],"(RT).":[21],"The":[22,206],"risk":[23,47,252,310,392,413,430,497,534,572,598,625,648,659,699],"of":[24,48,92,114,131,154,173,183,197,202,209,222,258,311,325,350,395,431,494,498,526,532,566,599,626,649,660,694,700,708],"t-AML":[25,49,138,169,303,345,363,396,432,449,499,533,571,600,627,650,661],"has":[26,573],"evolved":[27],"over":[28,50,535,551],"time":[29,518,671],"mostly":[30],"due":[31],"to":[32,178,254,318,369,439,447,480,513,523,690],"advances":[33],"therapeutics.":[36],"In":[37,555,614],"this":[38,71],"study,":[39],"we":[40,300,427,568,622],"provide":[41],"comprehensive":[43],"analysis":[44,336],"on":[45,151,337,684,697],"the":[46,65,90,128,141,195,198,225,231,244,249,256,286,319,351,376,412,429,496,552,594,597,618,624,658,692,698],"40-year":[52],"period":[53],"CTX":[59,283,295,440,458,486,559,577],"or":[61,181],"without":[62,435],"RT":[63,436,456],"US.":[66],"Methods:":[67],"Eligible":[68],"pts":[69,291,401,417,481,501,709],"for":[70,156,296,408,459,560,578,630,638,678],"study":[72,184,553,616],"were":[73,98,135,148,166,192,365,444,452,483],"identified":[74,149,301,530],"from":[75,213,224,541],"nine":[76],"Surveillance,":[77],"Epidemiology,":[78],"End":[80],"Results":[81],"Program":[82],"(SEER":[83],"9)":[84],"registries":[85],"included":[87,136,348],"those":[88],"between":[89,108],"ages":[91],"18":[93],"84":[95],"years":[96,379,525],"who":[97,482,557],"diagnosed":[99],"any":[101],"first":[102,129,297,338,377,562],"primary":[103,133,298,339,382,405,563],"malignancy":[104,134],"(other":[105],"than":[106,372,675],"CML)":[107],"1975-2018":[109,542],"received":[111,558],"initial":[112,280],"course":[113],"treatment":[115],"CTX.":[117],"All":[118,146],"cases":[120,304,327],"that":[121,262,570],"occurred":[122],"at":[123,234,342,710],"least":[124,343],"one":[125],"year":[126],"after":[127,576],"diagnosis":[130],"as":[137,139,194,285],"per":[140,264,267,328],"World":[142],"Health":[143],"Organization":[144],"classification.":[145],"malignancies":[147,340],"based":[150],"International":[152],"Classification":[153],"Disease":[155],"Oncology,":[157],"3rd":[158],"edition":[159],"(ICD-O-3)":[160],"morphology":[161],"topography":[163],"codes.":[164],"Subjects":[165],"followed":[167],"until":[168],"diagnosis,":[170,495],"attained":[171],"age":[172],"85":[174],"years,":[175,621],"death,":[176],"loss":[177],"follow":[179],"up,":[180],"end":[182],"(December":[185],"31,":[186],"2018).":[187],"Standardized":[188],"incidence":[189,220],"ratios":[190],"(SIRs)":[191],"calculated":[193,237,547],"ratio":[196],"observed-to-expected":[199],"(O/E)":[200],"number":[201,208,257],"using":[204,282,548],"SEER*Stat.":[205],"expected":[207,263],"was":[211,414,507,546,646],"computed":[212,248],"age-,":[214],"race-,":[215],"sex-,":[216],"calendar":[218,492],"year-specific":[219],"rates":[221],"general":[226,320,373],"SEER":[227],"population,":[228],"multiplied":[229],"by":[230,490],"appropriate":[232],"person-years":[233,330],"risk.":[235],"We":[236,246,269,333,528],"exact":[238],"95%":[239,314,423],"confidence":[240],"intervals":[241,540],"(CI)":[242],"about":[243],"SIRs.":[245],"also":[247,529],"excess":[250,259,275,324],"absolute":[251],"(EAR)":[253],"estimate":[255],"cancers":[260,349,406],"beyond":[261],"10,000":[265,329],"persons":[266],"year.":[268],"conducted":[270],"Poisson":[271],"regression":[272],"analyses":[273],"comparing":[274],"relative":[276],"risks":[277,364],"(ERR)":[278],"RT,":[281,567],"alone":[284,515,677],"reference.":[287],"Results:":[288],"Among":[289],"1,030,380":[290],"initially":[292],"malignancy,":[299,564],"2,081":[302],"4.76":[307],"fold":[308],"increased":[309,601],"(SIR;":[313],"CI,":[315,424],"4.55-4.96)":[316],"compared":[317,479,512,522],"population":[321],"an":[323],"3.94":[326],"(Table":[331,441,543],"1).":[332],"focused":[334],"our":[335,615],"100":[344],"cases,":[346],"which":[347,702],"lung,":[352],"breast,":[353],"ovaries,":[354],"Hodgkin":[355],"Lymphoma":[356,359],"(HL),":[357],"Non-Hodgkin":[358],"(NHL),":[360],"myeloma.":[362,655,682],"particularly":[366],"high":[367],"(six-":[368],"twenty-fold":[370],"higher":[371],"population)":[374],"5":[378],"following":[380,509],"these":[381,404,685],"diagnoses,":[384],"then":[385],"declined":[386,575],"substantially":[387],"increasing":[389,637,647,652],"latency.":[390],"Long-term":[391],"(\u226510":[393],"years)":[394],"remained":[397],"significantly":[398,574],"elevated":[399],"all":[403],"except":[407],"lung":[409,460,579,631],"highest":[415],"myeloma":[419,506,589,635],"(SIR":[420],"=":[421,586,591],"13.74;":[422],"8.27-21.46).":[425],"Additionally,":[426],"assessed":[428],"addition":[438],"2).":[442,544],"Pts":[443],"more":[445],"likely":[446],"develop":[448],"if":[450],"they":[451],"both":[455],"(ERR":[462,468,475],"1.85,":[463],"95%CI,":[464,470,477],"1.24-2.78),":[465],"breast":[466,603,639],"1.36,":[469],"1.13-1.65),":[471],"ovarian":[473],"1.70,":[476],"0.83-3.47)":[478],"alone.":[487],"When":[488],"analyzed":[489],"different":[491],"periods":[493,519,672],"HL,":[503,633,679],"NHL":[504,609,680],"lower":[508,674],"combined":[510,663],"modality":[511,664],"recent":[517,670],"(1997-2007,":[520],"2008-2018)":[521],"earlier":[524],"diagnosis.":[527],"trends":[531],"time,":[536],"displayed":[537],"11-year":[539],"Ptrend":[545],"annual":[549],"SIRs":[550],"period.":[554],"their":[561],"irrespective":[565],"found":[569],"(Ptrend":[581,585,590,605,610],"<":[582,606,611],"0.001),":[583],"HL":[584],"0.003),":[587],"0.001).":[592,612],"Over":[593],"same":[595],"period,":[596],"0.001)":[607],"Conclusions:":[613],"spanning":[617],"past":[619],"40":[620],"observed":[623],"trending":[628],"down":[629],"cancer,":[632],"while":[636],"NHL.":[642],"A":[643],"notable":[644],"finding":[645],"latency":[653],"Of":[656],"interest,":[657],"regimens":[665],"(CTX":[666],"RT)":[668],"Based":[683],"observations,":[686],"it":[687],"imperative":[689],"analyze":[691],"impact":[693],"newer":[695],"therapies":[696],"t-AML,":[701],"will":[703],"greatly":[704],"benefit":[705],"risk-benefit":[706],"counseling":[707],"individual":[711],"level.":[712],"Figure":[713],"1View":[714,717],"largeDownload":[715,718],"PPTFigure":[716],"PPT":[719],"Close":[720],"modal":[721]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2022-11-30T00:00:00"}